Search results
Results from the WOW.Com Content Network
A systematic review assessed 12 articles involving a total of 318 patients with hepatocellular carcinoma treated with Yttrium-90 radioembolization. [84] Excluding a study of only one patient, post-treatment CT evaluation of the tumor showed a response ranging from 29 to 100% of patients evaluated, with all but two studies showing a response of ...
Males are more often affected with hepatocellular carcinoma (HCC) than females. [3] Diagnosis is most frequent among those 55 to 65 years old. [2] The leading cause of liver cancer is cirrhosis due to hepatitis B, hepatitis C, or alcohol. [4] Other causes include aflatoxin, non-alcoholic fatty liver disease and liver flukes. [3]
Transformation to hepatocellular carcinoma is more common in men. [2] Currently, if the hepatic adenoma is >5 cm, increasing in size, symptomatic lesions, has molecular markers associated with HCC transformation, rising level of liver tumor markers such as alpha fetoprotein , the patient is a male, or has a glycogen storage disorder , the ...
The mRNA-based disease diagnosis technologies have been applied to medical field widely in recent years, especially on early diagnosis of tumors (such as renal cell carcinoma, [2] hepatocellular carcinoma, [3] [4] breast cancer [5] and prostate cancer [6]). The technology can be applied to various types of samples depending on how easily the ...
Park et al. conceptualized carcinogenesis of hepatocellular carcinoma (HCC) as a multistep process involving parenchymal arterialization, sinusoidal capillarization, and development of unpaired arteries (a vital component of tumor angiogenesis). All these events lead to a gradual shift in tumor blood supply from portal to arterial circulation.
In transplantation medicine, the Milan criteria are set of criteria applied in consideration of patients with cirrhosis and hepatocellular carcinoma (HCC) for liver transplantation with intent to cure their disease.
MASH can then lead to complications such as cirrhosis and hepatocellular carcinoma. [3] [5] [27] The new name, metabolic dysfunction-associated steatotic liver disease (MASLD), was proposed after 70% of a panel of experts expressed support for this name. [1] This new name was adopted in 2023. [1] [10]
Chronic liver disease in the clinical context is a disease process of the liver that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis. [1] "Chronic liver disease" refers to disease of the liver which lasts over a period of six months.